AZN vs JAZZ
AZN: AstraZeneca is a global pharmaceutical leader driving innovation in oncology, rare diseases, and specialized biopharmaceuticals to address major unmet medical needs worldwide. JAZZ: A rare-disease biopharmaceutical company with diversified marketed therapies in epilepsy, sleep disorders, and oncology, and an expanding pipeline of innovative treatments.
Side-by-side fundamentals
| Metric | AZN | JAZZ | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $169.64 | $252.86 | |
| Market cap as of 2026-08-04 | $195.9B | $15.9B | |
| P/E as of 2026-08-04 | 25.24 | 538.57 | AZN lower |
| PEG as of 2026-08-04 | 2.64 | 65.11 | AZN lower |
| Net margin as of 2026-08-04 | +17.0% | +0.7% | AZN higher |
| Gross margin as of 2026-08-04 | +81.3% | +88.0% | JAZZ higher |
| Operating margin as of 2026-08-04 | +22.8% | -0.8% | AZN higher |
| ROE as of 2026-08-04 | +21.7% | +0.7% | AZN higher |
| ROA as of 2026-08-04 | +9.1% | +0.3% | AZN higher |
| Debt / equity as of 2026-08-04 | 0.64 | 1.18 | AZN lower |
| Revenue growth (YoY) as of 2026-08-04 | +8.6% | +9.2% | JAZZ higher |
| Revenue CAGR (3y) SEC XBRL | +9.8% | +5.3% | AZN higher |
| Dividend yield as of 2026-08-04 | +2.1% | n/a | |
| Beta as of 2026-08-04 | 1.34 | 0.71 | |
| 1-year return as of 2026-07-27 close | +16.7% | +120.6% | JAZZ higher |
Fundamentals: market data, as of 2026-08-04. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.